Price movement over the last 24 hours
Alcon AG vs Uranium Energy Corp — how do they compare? Alcon AG trades at $66.87 (market cap $32.69B), while Uranium Energy Corp trades at $9.7 (market cap $4.90B). The key difference: Alcon AG is far larger — about 6.7× Uranium Energy Corp's market cap, and Alcon AG pays a 0.54% dividend while Uranium Energy Corp pays none. Which is the better fit depends on your goals.
| ALC | UEC | |
|---|---|---|
Market Cap | $32.69B | $4.90B |
Sector | Health | Energy |
52-Week High | $92.22 | $20.14 |
52-Week Low | $62.02 | $5.92 |
Enterprise Value | $36.28B | $4.41B |
Dividend Yield | 0.54% | — |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
UEC trades at $10.57, down 2.22% today, amid bearish technical signals and weak quarterly results. The stock shows negative profitability with a -513.24% net income margin and has missed earnings expectations in two of the last three quarters. However, analyst sentiment remains strongly positive with 87.5% buy ratings, supported by the company's strategic positioning in uranium production and substantial liquidity of $794 million with no debt.
The outlook is mixed: strong analyst support and nuclear sector tailwinds offer long-term potential, but near-term risks include persistent losses, high valuation multiples, and operational execution challenges. Investors should weigh the company's asset base and market position against its current financial performance and cost pressures.
Trailing returns across standard periods
Latest headlines on both assets
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →